Profound Medical (PROF) vs. Its Rivals Head to Head Survey
by Doug Wharley · The Cerbat GemProfound Medical (NASDAQ:PROF – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Profound Medical to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, valuation, dividends, earnings and risk.
Risk & Volatility
Profound Medical has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Profound Medical’s competitors have a beta of 2.55, indicating that their average share price is 155% more volatile than the S&P 500.
Profitability
This table compares Profound Medical and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profound Medical | -171.57% | -63.03% | -51.24% |
| Profound Medical Competitors | -278.23% | -150.07% | -21.87% |
Earnings and Valuation
This table compares Profound Medical and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Profound Medical | $16.10 million | -$42.57 million | -6.70 |
| Profound Medical Competitors | $1.87 billion | $138.21 million | 10.70 |
Profound Medical’s competitors have higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and target prices for Profound Medical and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profound Medical | 1 | 0 | 1 | 1 | 2.67 |
| Profound Medical Competitors | 4251 | 10479 | 18202 | 824 | 2.46 |
Profound Medical presently has a consensus target price of $11.50, suggesting a potential upside of 75.04%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.57%. Given Profound Medical’s stronger consensus rating and higher possible upside, research analysts clearly believe Profound Medical is more favorable than its competitors.
Summary
Profound Medical competitors beat Profound Medical on 7 of the 13 factors compared.
Profound Medical Company Profile
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.